



Resin Y90 for Metastatic Leiomyosarcoma

Dr. Zachary T. Berman

Associate Clinical Professor of Radiology
University of California, San Diego
San Diego, CA



This presentation reflects Dr. Berman's clinical experience with the TriNav[®] Infusion System. Dr. Berman is a consultant for TriSalus[™] Life Sciences and has been compensated for this content. Results are not predictive of outcomes in other cases.




Case Description

- 72-year-old female with a history of leiomyosarcoma in the liver
- Disease progressed on a systemic therapy
- Treated with resin Y90 microspheres using the TriNav LV
- Delivered TARE using TriNav to increase the T:N ratio


Angiography

Same contrast injection parameters (1cc/sec for 20cc with 15 sec delay) and same catheter tip placement

Traditional Microcatheter
MAA Mapping Procedure




TriNav LV
Radioembolization Procedure



Tumor enhancing angiographically using TriNav LV

Cone Beam CT

Traditional Microcatheter
MAA Mapping Procedure




TriNav LV
Radioembolization Procedure




Increased tumoral enhancement via TriNav LV

SPECT – Target Tumors

Traditional Microcatheter
MAA SPECT




TriNav LV
Y90 SPECT




Significantly better tumor targeting via TriNav LV

SPECT – Normal Liver

Traditional Microcatheter
MAA SPECT



TriNav LV
Y90 SPECT



Significantly less uptake to the normal liver via TriNav LV


Dosimetry Comparing Dose to Target 5cm Tumor

Tumor 1			Normal Liver		
MAA Estimated Dose Traditional Microcatheter			Y90 Actual Dose TriNav LV		
D99	26	Gy	D99	91	Gy
D98	26	Gy	D98	94	Gy
D95	30	Gy	D95	97	Gy
D90	34	Gy	D90	101	Gy
D70	45	Gy	D70	107	Gy
D50	54	Gy	D50	115	Gy
D2	79	Gy	D2	135	Gy
D1	79	Gy	D1	136	Gy

Normal Liver		
Actual Normal Liver TriNav LV		
D99	0	Gy
D98	0	Gy
D95	0	Gy
D90	0	Gy
D70	0	Gy
D50	0	Gy
D2	136	Gy
D1	144	Gy

2x increase in dose to Tumor 1 when TriNav LV was used, with 0 Gy going to the background liver

Follow-Up MRI



3-month follow-up MRI shows no residual enhancement and significant shrinkage of the targeted 5cm tumor



Indications For Use

The TriNav[®] and TriNav[®] LV Infusion Systems are intended for use in angiographic procedures. They deliver radiopaque media and therapeutic agents to selected sites in the peripheral vascular system.^{1,2}

Contraindications

The TriNav[®] and TriNav[®] LV Infusion Systems are not indicated for use in the vasculature of the central nervous system (including the neurovasculature) or central circulatory system (including the coronary vasculature).^{1,2}

Rx Only For the safe and proper use of TriNav[®] and TriNav[®] LV, refer to their individual Instructions for Use.

This content is sponsored by TriSalus Life Sciences[®]. Results are not predictive of outcomes in other cases.

1. TriSalus[™] TriNav[®] Infusion System, Instructions for Use
2. TriSalus[™] TriNav[®] LV Infusion System, Instructions for Use

